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The materials available for the Right Ventricular Outflow Tract (RVOT) reconstruction in patients 
with Tetralogy of Fallot (TOF)/pulmonary atresia come with the severe limitation of long-term 
degeneration and lack of growth potential, causing right ventricular dysfunction, aneurysm 
formation and arrhythmias, thus necessitating several high-risk reoperations throughout patients’ 
life. 
In this study, we evaluated the capacity of Mesenchymal Stem Cells (MSCs) derived from the 
Wharton’s Jelly (WJ-MSCs), the gelatinous inner portion of the umbilical cord, to grow and 
recellularize an extracellular matrix (ECM) graft in our optimised xeno-free, good manufacturing 
practice- compliant culture system. WJ-MSCs were phenotypically and functionally characterised 
by flow cytometry and multi-lineage differentiation capacity, respectively. The typical MSCs 
immunophenotype and functional characteristics were retained in our xeno-free culture system, as 
well as the capacity to grow and engraft onto a naturally occurring scaffold. Wharton’s Jelly MSCs, 
from both human and swine source, showed excellent capacity to recellularize ECM graft 
producing a living cell-seeded construct.  
In addition, we have provided an in vivo proof of concept of feasibility of the cellularised conduit, 
engineered with swine Wharton’s Jelly MSCs, to be used in a novel porcine model of main 
pulmonary artery reconstruction, where it showed good integration within the host tissue.  
Our study indicates that the addition of WJ-MSCs to the ECM scaffold can upgrade the material, 
converting it into a living tissue, with the potential to grow, repair and remodel the RVOT. These 
results could potentially represent a paradigm shift in paediatric cardiac intervention towards new 
modalities for effective and personalised surgical restoration of pulmonary artery and RVOT 
function in TOF/pulmonary atresia patients.  
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Surgery of Congenital Heart Defects (CHDs) has made fundamental achievements in the last 
decades, but there are still challenges related to the material used for correction (1). Premature 
failure of these grafts results in repeated operations during a patient’s life (2). Amongst these 
conditions, Tetralogy of Fallot (TOF) is the most common complex CHD. In its most severe form, 
TOF can also include atresia of the pulmonary artery and valve, requiring a total replacement of 
the RVOT. Nevertheless, nearly all conduits/patches used for pulmonary artery and RVOT 
reconstruction require replacement because of lack of growth potential and long-term 
degeneration, causing right ventricular dysfunction, aneurysm formation and arrhythmias (3, 4).  
Homograft have long been conduits of choice for RVOT reconstruction, however their limited 
availability, high costs and potential for allosensitization make them a less than ideal option (5-7). 
Alternate prosthetic conduits have been developed over the years, including Contegra (bovine 
jugular vein), porcine xenografts, or synthetic materials such as Dacron (polyethylene 
terephthalate) and Gore-Tex (polytetrafluoroethylene, PTFE). In particular, the latter one has been 
adopted as preferred choice by several institutions, due to its ready availability, low cost and lack 
of potential sensitization. However, the performance in terms of time to conduit explantation and 
development of conduit stenosis still remains comparable to the homograft, therefore there is no 
real clinical advantage other than cost/availability benefits (8).  
Hence, alternative approaches, which meet the requirements of biocompatibility, non-
immunogenicity and ready availability of an ideal scaffold, are needed. 
We have previously presented Tissue Engineering (TE) as a promising approach to overcome the 
limitation of current treatments. By combining the use of a porcine decellularized small intestinal 
submucosa (SIS), a naturally occurring and a clinically approved extracellular matrix (ECM) 
scaffold, and perinatal autologous mesenchymal stem cells (MSCs), we have created 
cardiovascular grafts, in the form of small size conduits and cardiac patches, with demonstrated 
superior regenerative properties and cardiovascular performances in vivo compared to the acellular 
counterpart (9-11). 
In the recent years, stem cells from foetal-associated tissues, such as placenta, amniotic fluid, 
amniotic membrane and umbilical cord have gained increasing popularity thanks to their 
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immediate availability at birth, which makes them ideal candidates for corrections of congenital 
pathologies (12-15). 
Congenital anomalies of the heart and its vessels are among the diseases that can benefit from the 
therapy with umbilical cord derived MSCs. In particular, the Wharton’s Jelly, the mucous 
proteoglycan-rich matrix surrounding the umbilical cord vessels, has been identified as the region 
of the umbilical cord homing the largest content of MSCs. These cells are accessible and endowed 
with extended plasticity, self-renewal capacity, long-term expansion and differentiation potential, 
as well as immunoprivileged properties (16-19). All these advantageous characteristics, in addition 
to the demonstrated capacity to form an optimal neo-matrix with excellent mechanical properties, 
make WJ-MSCs a promising and readily available cell source for cardio-vascular tissue 
engineering (20). Several experimental studies have been conducted so far to explore the feasibility 
of using WJ-MSCs to develop living materials for replacement of cardiovascular structures, mainly 
in the form of patches, heart valves and conduits (21-24). However, they have only provided an in 
vitro evidence of successful fabrication of biologically-active materials, with the exception of one 
pre-clinical case where a WJ-MSCs based heart valve has been validated in a large animal model 
(25).  
With the present study, for the first time, we have further upgraded the in vitro manufacturing 
process of the WJ-MSCs- engineered vascular conduit to clinical grade, good manufacturing 
practices (GMP)- compliant standards, which would be essential for the first in human clinical 
trial. Pilot in vivo data suggest that the engineered WJ-MSCs SIS (CorMatrix®) can be safely 
implanted in the main pulmonary artery position of a porcine animal model, indicating potential 











Human umbilical cord samples were collected at St. Michael Hospital (Bristol, UK), under 
informed consent from the mother, in accordance with the licence approved by the Southwest 
Research Ethics Committee (11/HO107/4). The investigation conformed to the principals outlined 
in the Declaration of Helsinki.    
Porcine umbilical cord samples were collected within 24 hours after birth from Landrace female 
piglets (average weight 1.5kg) sacrificed using schedule one, following the guidelines of the UK 
Home Office. Three to four-week-old female Landrace pigs (15 kg in body weight) were employed 
in the in vivo graft implantation studies under the UK Home Office ethical approval PPL 30/3019.  
Animals were treated in accordance with the “Guide for the Care and Use of Laboratory Animals” 
published by the National Institutes of Health in 1996 and conforming to the “Animals (Scientific 
Procedures) Act” published in 1986. 
Isolation and expansion of MSCs 
Umbilical cord samples were obtained from natural labour or caesarean delivery of termed 
pregnancy women. After few washings in phosphate-buffered saline (PBS, Life Technologies), 
the umbilical cord was cut open and vessels were removed. and MSCs were isolated by mechanic 
dissociation of the cord by removing 2 -3 cm2 segments from the inner gelatinous tissue. The finely 
minced tissues were distributed in a sterile petri dish and the culture medium poured slowly and 
gently, so as not to detach the fragments, which were then cultured in DMEM (Life Technologies) 
supplemented with 10% Hyclone Fetal Bovine Serum (FBS, Thermo Scientific) and FGF (2.5 
ng/µL, Peprotech) at 37°C in a humidified 5%CO2 incubator. Fresh medium was replaced after 5 
days and then changed every 3 days until the visible out-growth WJ-MSCs were observed. Upon 
reaching 70-80% confluency, cells were detached using Trypsin-EDTA (0.05%, Life technologies) 
and passaged to new flasks.  
The same protocol was applied to the isolation of WJ-MSCs under GMP conditions, whereby each 
culture medium component was replaced by the equivalent GMP product (GMP PBS, Sigma 




Fluorescent-Activated Cell Sorting analysis was used to determine cell surface markers expression 
at early passage (2) and later (4-5). The protocol was performed as previously described by our 
group (10) (9). The following primary antibodies were used for human WJ-MSCs: CD105 (1:20, 
R&D System), CD90 (1:5, R&D System), CD45 (1:20, R&D System), CD31 (1:20, BD 
Pharmingen), CD34 (1:40, eBioscience), CD73 (1:50, BD Pharmingen), CD44 (1:20, BD 
Pharmingen), CD40 (1:20, BD Pharmingen), HLA-DR (1:20, BD Pharmingen), CD166 (1:100, 
BD Pharmingen), CD 79alpha (1:10, BD Pharmingen), CD29 (1:5, BD Pharmingen), CD14 (1:10 
BD Pharmingen). Primary antibodies used against porcine WJ-MSCs were as follow: CD31 (1:10, 
Bio-Rad), CD44 (1:600, eBioscience), CD45 (1:25, Bio-Rad), CD73 (1:10, R&D Systems), CD90 
(1:20, Biolegend), CD105 (1:5, LSBio). Analysis was performed on a NovoCyte flow cytometer 
(ACEA Bioscience, Inc) using NovoExpress (ACEA Bioscience, Inc) for data collection and 
FlowJo (TreeStar, Ashland) for analysis. 
In vitro multilineage differentiation 
In vitro multi-lineage differentiation into osteocytes, adipocytes and chondrocytes was performed 
with MSCs at passage between 3 and 5. Cells were cultured in alpha-MEM medium with specific 
StemXVivo supplement kits (R&D system) for different time points. Osteogenic differentiation 
was assessed after 3 weeks of culture using Alizarin Red (Sigma-Aldrich) to detect calcium depo-
sition. Oil Red O staining (Sigma-Aldrich) was used to detect lipid accumulation of cells under-
going 2 weeks of adipogenic differentiation. Alcian Blue staining (Sigma-Aldrich) was used to 
determine chondrogenic cartilage formation after 3 weeks of cell culture. 
In vitro functional studies 
All in vitro experiments assessing differences throughout expansion were set up with cells at P2, 
P4, P6, P8, P10 and P12 (P4 to P12 for senescence assay) under the same experimental settings. 
CFU-F (colony forming unit-fibroblast) assay was performed by seeding cells at very low density 
(100 cells/cm2) in a culture petri dish. After 2 weeks, the dishes were stained with 3% Crystal 
violet (Sigma) and the number of colonies was counted. For proliferation assessment, the BrdU 
immunofluorescence assay (Roche) was used, according to the manufacturer's instructions. The β-
galactosidase Senescence Detection kit (Calbiochem) was used as a biomarker of senescence in 
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MSCs. The percentage of senescent cells was represented by the number of β-galactosidase stained 
cells in total population. All in vitro assays were performed in triplicate wells and in 6 independent 
experiments. 
Graft cellularization and maturation in a bioreactor  
Decellularized porcine small intestinal submucosa (CorMatrix® Cardiovascular, Inc, USA) was 
seeded with WJ-MSCs (p2 to p4) at a density of 2.5x105 /cm2 and maintained under static 
conditions for 3 days. The engineered-graft was then stitched to the rotating arm of an InBreath 
bioreactor (Harvard Apparatus, USA) as to fashion a conduit-shape with the cells facing the outer 
side of the graft. The rotation was set at 1.5 rpm for the first 24 hours, and then at 2 rpm for 7 days, 
after which the viability of the seeded cells was assessed by a fluorescent viability/cytotoxcitity 
assay (Life technologies) according to the manufacturer’s instruction. Seeded grafts were images 
on a Zeiss Axio Observer.Z1 with Zen Blue software (Zeiss).  
Mechanical testing of the engineered graft 
Acellular and cell-seeded SIS pieces were analysed for mechanical properties using an Instron 
3343B machine (Instron, UK) with a 100 N load cell and pneumatic grips. Crosshead speed was 
100 mm/min. Samples were measured for tensile stress at break using a Bluehill software (Instron, 
UK). 
In vivo implantation of the porcine WJ-MSCs- cellularized conduit in piglet main Pulmonary 
Artery 
Two Landrace female pigs (3-4 weeks old) of 15-20 kg were employed in this study. 
The SIS was engineered with porcine WJ-MSCs, whose isolation, characterization and graft 
engineering were performed following the same protocol used for the human WJ-MSCs. Surgical 
procedures were performed under general anaesthesia (Ketamine/Midazolam/ Dexmedetomidine, 
Isoflurane) and neuromuscular blockade (Pancuronium Bromide), and the heart was accessed by 
median sternotomy. Cardiopulmonary bypass (CBP) was then established by cannulating the 
inferior and superior vena cava and the ascending aorta. On the beating heart 8 mm of the main 
pulmonary artery was excised just above the pulmonary valve up to the pulmonary artery 
bifurcation and the tissue engineered conduit implanted as an interposition graft. Animal cardiac 
functions were monthly monitored with Doppler Echocardiography and, after 6 months from 
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implantation, were scanned with a magnetic resonance (MRI) and euthanized. Pulmonary arteries 
were dissected from the heart and fixed in 4% PFA or fresh-frozen in liquid nitrogen.  
 
Histological analysis 
For paraffin embedding, samples were fixed in 4% PFA, washed in PBS, moved into cassettes 
(Histosette I, Simport), processed in a Thermo Excelsior AS, and embedded in a Thermo HistoStar 
machine. A Sandon Finesse 325 (Thermo) microtome was used to cut 5 µm sections which were 
floated onto Menzel-Glaser SuperFrost Plus slides (Thermo). Slides were stored at 37oC overnight 
to dry completely before staining. Hematoxylin and eosin (H&E) and van Gieson’s (EVG) stains 
were performed using a Shandon Varistain 24-4 (Thermo). Slides were removed from machine 
and mounted with DPX (distyrene, a plasticizer, in toluene-xylene; Sigma) with 24 x 50 mm cover 
glass (VWR). Slides were imaged on a Zeiss Axio Observer.Z1 with Zen Blue software (Zeiss). 
Von Kossa staining was carried out with a Silver plating kit (In Vitro Diagnostic Medical Device) 
for detection of microcalcification. 
Fluorescent immunohistochemistry  
Paraffin-embedded sections were deparaffinized by two changes of clerene and rehydrated through 
an alcohol gradient. A heated antigen retrieval with 10mM citrate buffer pH 6.0 was performed. 
Samples were blocked with 10% goat serum (Sigma-Aldrich) in PBS for 30 minutes at RT and 
incubated with the unconjugated primary antibodies (α-SMA, 1:100, SIGMA; Isolectin B4-Biotin 
1:100, Life Technologies) overnight at 4°C. Fluorophore-conjugated secondary antibodies (Alexa 
Fluor 488 and Alexa Fluor 546, 1:400, Life Technologies) were incubated on the sections for 1 
hour at room temperature in the dark.  Nuclei were counterstained with DAPI (1:1000; Sigma-
Aldrich) for 10 minutes at room temperature. Slides were mounted with Hardset mounting medium 
(Vectashield). Images were taken with a Zeiss Observer.Z1 fluorescent microscope. 
Scanning Electron Microscopy (SEM) 
PFA-fixed samples were washed in 0.1 M phosphate buffer and then fixed in osmium tetroxide in 
phosphate buffer. After washing in phosphate buffer, samples were dehydrated through an alcohol 
gradient ending with three changes of absolute alcohol. Sample were dried in a critical point dryer 
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(Leica EM CPD300). They were finallycoated at 100 mAfor 30s using EMITECH K575X sputter 
coater and observed using a quanta 400 FEI scanning electron microscope.  
Statistical Analysis 
Data are expressed as mean ± SEM. Samples were analyzed by Student’s t test or One-way 






















Isolation and characterization of human Wharton’s Jelly- derived Mesenchymal Stem 
Cells (WJ-MSCs) 
After vessels removal from the human umbilical cord received upon delivery, Wharton’s Jelly 
segments were obtained by mechanical dissociation of the cord and placed into culture flasks. 
Outgrowing human WJ-MSCs from the adhering tissues were observed in 7 to 12 days (P0), after 
which time they proliferated rapidly in the expansion medium, acquiring a higher degree of 
morphological homogeneity throughout passages (Figure 1). Flow cytometry immunoprofiling 
demonstrated that all preparations exhibited the main typical MSCs surface markers (CD29, CD44, 
CD73, CD90, CD105) and lacked expression of the hematopoietic (CD34), leucocytes (HLA-DR, 
CD45), monocytes (CD14), B cell (CD79alpha), and endothelial cells markers (CD31) (Figure 2 
a, b). The gold standard for functional characterization of MSCs is the ability to differentiate 
towards more than one cell type. Our results confirmed that WJ-MSCs have the potential to 
differentiate into adipogenic, osteogenic and chondrogenic phenotype, as demonstrated by Oil Red 
O, Alizarin Red and Alcian Blue staining respectively (Figure 2c).  
Incorporation of WJ-MSCs in a clinical-grade scaffold and maturation of the tissue 
engineered conduit in a dynamic bioreactor 
The feasibility of using WJ-MSCs as a cell source for cardiovascular tissue engineering was next 
investigated. We used an optimised method, previously developed and described by our group, to 
seed WJ-MSCs onto the SIS and grow the resulting cell-seeded construct under static then dynamic 
conditions. These latter were reproduced by accommodating the graft in a conduit shape fashion 
into a bioreactor. The generated flow, provided by rotating stirrers, ensures that nutrients and O2 
are homogenously diffused to the three-dimensional construct, thus priming the cells to the 
dynamic condition they would be exposed to in vivo. Human WJ-MSCs showed excellent cell 
attachment and growth as demonstrated by the calcein positive staining of the viable cells and the 
H&E histological staining of the nuclei that evenly populated the seeded scaffold (Figure 3 a v, 
vi). Scanning electron microscopy further showed the progressive tissue formation, with a 
confluent cell layer on the SIS surface.  (Figure 3 a viii). In seeded conduits, a higher signal 
intensity of collagen was detected, as compared to unseeded conduit, meaning that WJ-MSCs were 
able to synthesize their own extracellular matrix components (Figure 3 a iii, vii). We confirmed 
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that the multicell layer maintained its original phenotype as showed by the expression of the MSCs 
marker CD44, after the culture of the conduit under the flow provided by the bioreactor (Figure 3 
b). No difference was found among the mechanical properties of the WJ-MSCs-engineered 
constructs, in terms of strength and stiffness, as demonstrated by comparable values of Ultimate 
tensile strength and Young’s modulus of elasticity (Figure 3 c). 
Optimization of a GMP-grade culture system of the human WJ-MSCs engineered conduit 
for clinical translation in cardiac paediatric surgery 
For the clinical translation of the WJ-MSCs- derived engineered vascular graft, we have next set 
up a standard operating procedure (SOP) to expand human WJ-MSCs under xeno-free, GMP-
compliant conditions, an essential requirement for clinical applications to exclude the risk of 
transmission of unknown infectious agents. 
Phenotypic analysis of WJ-MSCs cultured under GMP compliant conditions revealed that cells 
expressed the typical MSCs markers and lacked immune, hematopoietic and endothelial markers, 
with these features being retained after a cycle of freezing and thawing, a step that might be 
required to meet the surgical schedule (Figure 4 a). In addition, the multipotent differentiation 
capacity was conserved, after culture in adipogenic, osteogenic and chondrogenic-supplemented 
media in both fresh (Figure 4 b) and frozen cell culture (data not shown). 
Moreover, cells functional behaviour was not affected by the change of medium composition. 
BrdU incorporation and CFU assay revealed that human WJ-MSCs cultured under GMP 
conditions exhibit a rather superior growth rate compared to standard, not xeno-free culture 
system, with this being statistically significant at P6 and P2/P8 respectively (Figure 4 c, d). The 
incidence of senescence was significantly lower at higher passages (P10, P12) in the GMP-
condition compared to the standard (Figure 4 e). The cells proliferative capacity and engraftment 
on the SIS in GMP conditions was likewise retained, which is paramount for the clinical-grade 
realization of the engineered vascular graft using MSCs derived from Wharton’s Jelly tissue 
(Figure 4 f).  




The standard operative protocol for isolation and expansion of human WJ-MSCs has been 
successfully adapted to obtain MSCs from porcine umbilical cord, to be used for the autologous 
implantation into the swine model. Flow cytometry of all cell lines analysed confirmed the typical 
MSCs phenotypical features and functional differentiation capacity of the swine WJ-MSCs of the 
swine WJ-MSCs (Figure 5 a-c). The ability of the swine cells to adhere and proliferate on the SIS, 
resulting into a mechanically sound tissue engineered conduit, was also confirmed (Figure 5 d, e). 
In vivo integration and remodelling of swine WJ-MSCs -engineered conduit within the host 
pulmonary artery tissue 
To assess the in vivo safety and efficacy of the engineered vascular conduit produced in vitro 
(Figure 6 a, i-ii), we have developed a new piglet model consisting of main pulmonary artery 
reconstruction (Figure 6 a, iii) with the WJ-MSCs derived conduit or the acellular counterpart. 
Pilot echocardiography data show that at 6 months follow up, the conduits were patent with no 
stenosis, rupture, or deformation (Figure 6 b).  
Macroscopic observation of the explanted WJ-MSCs- seeded conduit showed smooth luminal 
surfaces without signs of thrombosis and tissue degradation (Figure 6 a, iv, v). Histological H&E 
images show extensive nucleation throughout the structure of seeded and unseeded grafts (Figure 
6 c). Interestingly, however, a higher content of elastin, the major extracellular matrix component 
of the pulmonary artery, was visible in the seeded graft (Figure 6 d). No sign of calcification was 
detected either in the explanted seeded or acellular grafts (Figure 6 e). Moreover, only in the 
cellularised conduit, we could detect a highly organised layer of smooth muscle cells populating 
the tunica media, and a newly formed layer of endothelial cells, resembling the structure of the 
native pulmonary artery (Figure 6 f). In line with this latter finding, a confluent layer of endothelial 
cells could be detected through scanning electron microscopy of the luminal side of the cellularised 








In the present study, we showed the Wharton’s Jelly as suitable source of MSCs for tissue-
engineering cardiovascular replacement grafts. Furthermore, our pilot data provided an in vivo 
proof of concept that the WJ-MSCs engineered graft can be safely implanted in the main 
Pulmonary Artery position of a porcine animal model reproducing part of the clinical scenario of 
Tetralogy of Fallot/pulmonary atresia surgical correction in infants. Umbilical cord is becoming 
increasingly popular for regenerative medicine applications required soon after birth (12, 13). 
Particularly, the Wharton’s Jelly is the home of a large number of MSCs that can be easily 
harvested and expanded. These cells exhibit higher plasticity, self-renewal capacity, differentiation 
potential and immunoprivileged properties than MSCs from other sources (16-18). Importantly, 
the availability of the umbilical cord at birth has the great advantage of providing an ethically 
acceptable source of cells that can be immediately harvested and expanded in order to provide a 
therapeutic tool for congenital defects that require a surgical intervention few weeks or months 
after birth, like TOF/pulmonary atresia correction. 
While most of previous studies have demonstrated in vitro successful fabrication of biologically-
active materials using WJ-MSCs (21-24), our study showed in vivo successful use of WJ-MSCs-
based construct in a large animal model of main Pulmonary Artery reconstruction surgery. To our 
knowledge, only one previous pre-clinical study has demonstrated the implantation of WJ-MSCs 
based heart valve in a large animal model (25). Precisely, WJ-MSCs were seeded on biodegradable 
matrices to generate living trileaflet heart valves that have been successfully implanted in sheep 
models up to 20 weeks showing good functional performance and structural characteristics (25). 
We have used the SIS, as the ECM scaffold to support the growth and maturation of WJ-MSCs 
into a living tissue. SIS (Cormatrix®) has received approval by both the Food and Drug 
Administration and European authorities for cardiac tissue repair and is being used in various 
clinical applications of cardiovascular surgery, thanks to its excellent physical properties, 
including resistance to deformation, easy handling and shaping, suture retention, good 
absorbability, and lack of immunogenicity [Web Ref. 1]. However, recent pre-clinical studies 
using the SIS fashioned as a trileaflet valved conduit in a pig model of thoracic aorta replacement 
showed that this model failed to remodel in a structural and anatomical manner, leading to early 
fibrosis and calcification (26). Similar concerns were raised by studies using SIS-ECM for valve 
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repair in children (27). Nevertheless, our group has previously demonstrated that, compared to the 
acellular products, the presence of the MSCs on the SIS favoured the remodelling and regeneration 
of the graft in piglet models of RVOT reconstruction and Left Pulmonary Artery replacement, 
respectively (10, 11). The animal model developed in this study, whereby the Main Pulmonary 
Artery is replaced by the engineered conduit, allowed us to optimize a surgical procedure suitable 
for pre-clinical and pediatric clinical application, while providing a proof of concept of the safety 
of our WJ-MSCs-seeded SIS.  
The porcine species was chosen for its widely accepted recognition as a suitable animal model in 
cardiovascular research, owning to its similarity to humans in terms of cardiovascular anatomy 
and physiology (28, 29). Therefore, the ECM scaffold engineered with porcine WJ-MSCs was 
used for the in vivo study. The use of an allogeneic cellular product avoids the risks of cross-
species immunogenic responses and of an increased susceptibility to infections that would derive 
from immunosuppressive therapy, with the ultimate effect of overshadowing any potential benefit 
related to the product.  
The surrogate cell product we have produced for the pre-clinical study was validated through 
extensive characterization of the cells phenotype, function and capacity to integrate and give rise 
to a living tissue, equivalent to the human counterpart. The results of our pilot in vivo study 
indicates the safety of a decellularized scaffold repopulated with Wharton’s Jelly- derived cells to 
reconstruct the main pulmonary artery and its capacity to grow and remodel in a large animal 
model. Compared to the acellular counterpart, the seeded conduit displayed a remarkably 
organised layer of Smooth Muscle Cells, which are most likely endogenous cells recruited from 
the recipient tissue as our previous study investigating the fate of the implanted donor cells showed 
that no cells were detected in the explanted graft at 4 months post-operation (9, 10).  
Furthermore, the new endothelialisation observed on the luminal side of the graft supports the 
paracrine activity typically associated to MSCs in driving vascular cells recruitment from the 
adjacent vascular tissue, which we also reported in our previous studies where a high content of 
paracrine and trophic factors released by MSCs was detected in the culture  medium (9, 10).  
While a pre-clinical controlled randomized efficacy/safety study based on the proposed technology 
is currently ongoing, we have pre-emptively established a successful manufacturing process, from 
WJ-MSCs isolation throughout the production of the graft, in GMP-compatible conditions, strictly 
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required for the clinical application of cell based medical produces. The results obtained from a 
systematic comparison between WJ-MSCs cultured under standard procedures, involving the use 
of xenogenic supplements, and GMP conditions showed that the optimised xeno-free, GMP 
compliant culture system did not compromise the quality of the cells and the final product, 
suggesting that WJ-MSCs can easily fulfil the need of clinical scale production. This is a 
remarkable result, considering that initial cell adhesion and growth in xeno-free cultures still 
remains a major problem for many cell types when switching from animal-derived products.   
Limitations 
Although the Proof of Concept of suitability of the Wharton’s Jelly-Mesenchymal Stem Cells- 
engineered conduit for TOF correction showed favourable outcome, a full-scale study is needed 
to prove the efficacy and superiority of our tissue engineered product compared to the currently 
used acellular SIS-ECM. A controlled randomized efficacy/safety study based on this technology 
is currently ongoing. 
CONCLUSIONS 
Our study demonstrates that the functionalization of the SIS scaffold with WJ-MSCs can upgrade 
the material, converting it into a living tissue, with the potential to grow, remodel and repair when 
implanted into an in vivo porcine model of pulmonary trunk replacement. Furthermore, we have 
established a GMP-compliant protocol for a human WJ-MSCs-derived vascular graft for its 
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